Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,230 | 2,834 | 4,889 | 9,462 | 7,227 |
| Inventories | N/A | N/A | 2,645 | 1,285 | 590 |
| TOTAL | $3,434 | $3,033 | $8,024 | $12,094 | $8,208 |
| Non-Current Assets | |||||
| PPE Net | 69 | 112 | 236 | 131 | 212 |
| Other Non-Current Assets | 949 | 3,610 | 1,014 | 649 | 345 |
| TOTAL | $1,019 | $3,721 | $1,250 | $781 | $557 |
| Total Assets | $4,452 | $6,754 | $9,274 | $12,875 | $8,765 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 29 | 29 | N/A | N/A |
| Accounts payable and accrued liabilities | 508 | 701 | 1,523 | 1,411 | 910 |
| TOTAL | $605 | $903 | $1,704 | $1,544 | $987 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | 29 | 337 |
| Other Non-Current Liabilities | 1,287 | 192 | 366 | 518 | 272 |
| TOTAL | $1,287 | $192 | $366 | $547 | $609 |
| Total Liabilities | $1,892 | $1,095 | $2,070 | $2,090 | $1,596 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 562 | 6 | 2 | 1 | 1 |
| Common Shares | 0 | 0 | 0 | 0 | 3 |
| Retained earnings | -103,438 | -91,930 | -81,870 | -68,691 | -57,339 |
| Other shareholders' equity | 0 | 5 | 6 | 14 | 11 |
| TOTAL | $2,560 | $5,659 | $7,205 | $10,784 | $7,169 |
| Total Liabilities And Equity | $4,452 | $6,754 | $9,274 | $12,875 | $8,765 |